NEW ORLEANS — In this Healio Video Perspective from the AAO meeting, David S. Boyer, MD, discusses 6-month results of the DAVIO trial, investigating EYP-1901 (EyePoint Pharmaceuticals) in patients with wet AMD.
Uncategorized
VIDEO: EYP-1901 found to be ‘extremely safe,’ efficacious in first results